The planned 10,300 sq metre facility in Hillerød, north of Copenhagen, broke ground this afternoon at Brennum Park.
The site will produce and perform fill-finish for insulin and Saxenda (liraglutide), Novo Nordisk’s recombinant DNA weight loss therapy. It will also have production capacity for existing and future diabetes treatments.
Diabetes care is Novo Nordisk’s biggest earner, bringing 21.6m Danish kroner ($3.2m) of revenue to the company in Q3 this year. Biopharmaceuticals earned 5.2m kroner ($760,000) in the same quarter. The company reported earnings of 88.8m kroner ($13m) last year.
“The investment in Hillerød underscores our long-term ambition to create and maintain jobs in Denmark. This year alone we have created 1,000 new jobs in Denmark, of which 500 are in production, primarily in Kalundborg and Hillerød,” said Henrik Wulff, executive vice president and head of product supply, Novo Nordisk.
The ground-breaking ceremony was attended by the mayor of Hillerød, Dorte Meldgaard.